PREVALENCE AND RISK FACTOR OF POLYCYSTIC OVARIAN SYNDROME

Authors

  • Shaiba Sana Qureshi
  • Jeetendra Kumar Gupta GLA University
  • Kamal Shah
  • Neeraj Upmanyu

Abstract

ABSTRACT
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women. Its clinical manifestation varies from mild to severe
disturbance of reproductive and metabolic functions. PCOS is clinical and public health importance because it is affecting up to one in five women
of reproductive age. It is an X-linked dominant condition and has diverse clinical implications such as psychological features (anxiety, depression),
reproductive features (hirsutism and hyperandrogenism), and impaired glucose tolerance. It is widely dependent on environmental, genetic, ethnicity
factors including lifestyle and body weight. Weight loss improves the endocrine profile and increases chances of ovulation and pregnancy. It can
be treated with medications such as clomiphene citrate, tamoxifen, aromatase inhibitors, and gonadotrophins. The last option for fertilization is
in vitro fertilization when other treatment fails. Its prevalence is estimated at 4-8% from studies performed in Spain and USA. Lifestyle including diet,
exercise, and behavior therapy improves fertility. PCOS has unique interactions with the ever increasing obesity prevalence worldwide as obesityinduced
insulin resistance
significantly
aggravates
all the
features
of PCOS.
Education
about
how
PCOS
affects
long-term
health should
be provided

to
women
with this disorder
to
feel
physical
and psychological
benefits so that they
could engage
themselves
more
with their health care
providers.
Keywords: Polycystic ovarian syndrome, Hyperinsulinemia, Hormone disbalance, Hirsutism, Ovarian cyst, Obesity, Sleep disorders.

Downloads

Download data is not yet available.

Author Biography

Jeetendra Kumar Gupta, GLA University

Division of Pharmacology, Assistant Professor

References

REFERENCES

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A

complex condition with psychological, reproductive and metabolic

manifestations that impacts on health across the lifespan. BMC Med

;8:41.

Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA,

Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary

syndrome in the Greek island of Lesbos: Hormonal and metabolic

profile. J Clin Endocrinol Metab 1999;84(11):4006-11.

Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR,

Azziz R. Prevalence of the polycystic ovary syndrome in unselected

black and white women of the southeastern United States: A prospective

study. J Clin Endocrinol Metab 1998;83(9):3078-82.

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ,

Davies MJ. The prevalence of polycystic ovary syndrome in a

community sample assessed under contrasting diagnostic criteria. Hum

Reprod 2010;25:544-51.

Alvarez-Blasco F, Botella-Carretero JI, San Millán JL,

Escobar-Morreale HF. Prevalence and characteristics of the polycystic

ovary syndrome in overweight and obese women. Arch Intern Med

;166(19):2081-6.

Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J,

Stephens KC, et al. Androgen excess in women: Experience with over

consecutive patients. J Clin Endocrinol Metab 2004;89(2):453-62.

Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight

loss in obese infertile women results in improvement in reproductive

outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-5.

Legro RS, Strauss JF. Molecular progress in infertility: Polycystic

ovary syndrome. Fertil Steril 2002;78(3):569-76.

Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Ovarian

steroids modulate neuroendocrine dysfunction in polycystic ovary

syndrome. J Endocrinol Invest 2005;28(10):882-92.

Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance

in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol

Surv 2004;59(2):141-54.

Vrbíková J, Cibula D, Dvoráková K, Stanická S, Sindelka G, Hill M,

et al. Insulin sensitivity in women with polycystic ovary syndrome.

J Clin Endocrinol Metab 2004;89(6):2942-5.

Moran L, Teede H. Metabolic features of the reproductive phenotypes

of polycystic ovary syndrome. Hum Reprod Update 2009;15(4):477 88.

Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS,

et al. Differences in clinical and endocrine features between obese and

non-obese subjects with polycystic ovary syndrome: An analysis of 263

consecutive cases. Clin Endocrinol (Oxf) 1990;32(2):213-20.13.

Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G,

Braunstein GD, et al. Postmenopausal women with a history of

irregular menses and elevated androgen measurement at high risk

of worsening cardiovascular event -free survival: Results from the

National Institutes of Health--National Heart, Lung, and Blood Institute

sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol

Metab 2008;93(4):1276-84.

Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment

of obesity in polycystic ovary syndrome: A position statement of the

androgen excess and polycystic ovary syndrome society. Fertil Steril

;92(6):1966-82.

Balen A, Michelmore K. Prevalence of polycystic ovaries in

the women with anovulation and idiopathic hirsutism. Oxford J

;17(9):2219-27.

Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S,

Escobar-Morreale HF. A prospective study of the prevalence of the

polycystic ovary syndrome in unselected Caucasian women from

Spain. J Clin Endocrinol Metab 2000;85:2434-8.

Balen A. Pathogenesis of polycystic ovary syndrome – The enigma

unravels? Lancet 1999;354(9183):966-7.

Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update

;7(6):522-5.

Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ,

West C, et al. Polycystic ovary syndrome: The spectrum of the disorder

in 1741 patients. Hum Reprod 1995;10(8):2107-11.

Botsis D, Kassanos D, Pyrgiotis E, Zourlas PA. Sonographic incidence

of polycystic ovaries in a gynecological population. Ultrasound Obstet

Gynecol 1995;6(3):182-5.

Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does

ethnicity influence the prevalence of adrenal hyperandrogenism and

insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol

;167(6):1807-12.22.

Clarke AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X,

et al. Weight loss results in significant improvements in pregnancy

and ovulation rates in anovulatory obese women. Hum Reprod

;10(10):2705-12.

Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S,

et al. How common are polycystic ovaries in normal women and what

is their significance for the fertility of the population? Clin Endocrinol

(Oxf) 1992;37(2):127-34.

Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic

ovary syndrome: Clinical, endocrine and ultrasound features in

patients. Clin Endocrinol (Oxf) 1989;30(4):459-70.

Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P,

Lemaitre L, et al. Ovarian stromal hypertrophy in hyperandrogenic

women. Clin Endocrinol (Oxf) 1994;41(5):557-62.

Badawy A, Elnashar A. Treatment option for PCOD. Int J Women’s

Health 2011;3:25-35.

Speroff L, Fritz MA. Anovulation and the polycystic ovary. Clin

Gynecol Endocrinol Infertil J 2005;470:470-83.

Azziz R. Diagnostic criteria for polycystic ovary syndrome:

A reappraisal. Fertil Steril J 2005;83(3):1343-6.

Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P.

Polycystic ovary syndrome, diabetes and cardiovascular disease: Risks

and risk factors. J Obstet Gynaecol 2004;24(6):613-21.

Ehrmann DA. Polycystic ovarian syndrome. Engl J Med

;12:1223-36.

Dunaif A. Insulin resistance and the polycystic ovary syndrome:

Mechanism and implications for pathogenesis. Endocr Rev

;18(6):774-800.

Azziz R, Carmina E, Dewailly D. Position statement: Criteria

for defining polycystic ovary syndrome as a predominantly

hyperandrogenic syndrome: An androgen excess society guideline.

J Clin Endocrinol Metab 2006;91(11):4237-45.

Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian

morphology with regular ovulatory cycles: Insights into the

pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol

Metab 2004;89(9):4343-50.

Barber TM, Franks S. Metabolism characteristics of women with

polycystic ovaries and oligo-amenorrhoea but normal androgen level:

Implication for the management for the management of polycystic

ovarian syndrome. Oxford J 2007;66(4):513-7.

Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity

and reproductive disorder in women. Hum Reprod J 2003;9(4):359-72.

Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC,

Macklon NS. A meta-analysis of pregnancy outcomes in women with

polycystic ovary syndrome. Hum Reprod Update 2006;12(6):673-83.37.

Gjønnaess H. Ocarian electrocautery in the treatment of women

with polycystic ovarian syndrome. Acta Obstet Gynecol Scand

;73(5):407-12.

Patel SM, Nestler JE. Fertility in polycystic ovary syndrome. Endocrinol

Metab Clin North Am 2006;35:137-55, vii.

Reaven GM. The insulin resistance syndrome: Definition and dietary

approaches to treatment. Annu Rev Nutr 2005;25(1):391-406.

Bruner B, Chad K, Chizen D. Effects of exercise and nutritional

counseling in women with polycystic ovary syndrome. Appl Physiol

Nutr Metab 2006;31(4):384-91.

Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle

modification in polycystic ovarian syndrome. Reprod Biomed Online

;12(5):569-78.

Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F,

Sancho J, San Millán JL. The polycystic ovary syndrome associated

with morbid obesity may resolve after weight loss induced by bariatric

surgery. J Clin Endocrinol Metab 2005;90(12):6364-9.

Homburg R. Clomiphene citrate – end of an era? A mini-review. Hum

Reprod 2005;20(8):2043-51.

Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP,

Carson SA, et al. Clomiphene, metformin, or both for infertility in the

polycystic ovary syndrome. N Engl J Med 2007;356(6):551-66.

Messinis IE. Ovulation induction: A mini review. Hum Reprod

;20(1):2688-97.

Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends

Endocrinol Metab 2003;14(8):365-70.

Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis.

Circulation 2002;105(23):2696-8.

Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight

loss in obese women with polycystic ovary syndrome: Comparison of

doses. J Clin Endocrinol Metab 2005;90(8):4593-8.

Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes

among women with polycystic ovary syndrome treated with metformin.

Hum Reprod 2002;17(11):2858-64.

Published

01-03-2016

How to Cite

Qureshi, S. S., J. K. Gupta, K. Shah, and N. Upmanyu. “PREVALENCE AND RISK FACTOR OF POLYCYSTIC OVARIAN SYNDROME”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 23-25, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/10202.

Issue

Section

Review Article(s)